Anti-Omomyc [21-1-3]

Catalogue number: 153657
Sub-type: Primary antibody
Images:

Contributor

Inventor: Laura Soucek
Institute: Vall D'Hebron Institute Of Oncology (VHIO)
Images:

Tool details

***FOR RESEARCH USE ONLY**

Name: Anti-Omomyc [21-1-3]

Alternate name:

Class: Monoclonal
Conjugate: Unconjugated
Description: Monoclonal antibody specific for Omomyc, capable of suppressing Myc-induced oncogenesis. Omomyc is a dominant-negative allele of the proto-oncogene Myc (c-Myc). Omomyc is a mutant bHLHZip domain that sequesters Myc in complexes that are unable to bind to the E box recognition element and activate transcription but remain competent for transcriptional repression. Expression of Omomyc can induce rapid tumour regression in mouse models with little toxicity for normal tissues, acting as a suppressor of Myc-induced oncogenesis.
Purpose:
Parental cell:
Organism:
Tissue:
Model:
Gender:
Isotype: IgG2a kappa
Reactivity: Human
Selectivity:
Host: Mouse
Immunogen:
Immunogen UNIPROT ID:
Sequence:
Growth properties:
Production details:
Formulation:

Recommended controls:
Bacterial resistance:
Selectable markers:
Additional notes:

Target details

Target: Omomyc

Target alternate names:

Target background: Monoclonal antibody specific for Omomyc, capable of suppressing Myc-induced oncogenesis. Omomyc is a dominant-negative allele of the proto-oncogene Myc (c-Myc). Omomyc is a mutant bHLHZip domain that sequesters Myc in complexes that are unable to bind to the E box recognition element and activate transcription but remain competent for transcriptional repression. Expression of Omomyc can induce rapid tumour regression in mouse models with little toxicity for normal tissues, acting as a suppressor of Myc-induced oncogenesis.

Molecular weight:

Ic50:

Applications

Application: ELISA ; IHC ; IF ; WB
Application notes:

Handling

Format: Liquid
Concentration: 1 mg/ml
Passage number:
Growth medium:
Temperature:
Atmosphere:
Volume:
Storage medium:
Storage buffer: PBS with 0.02% azide
Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
Shipping conditions: Shipping at 4° C

Related tools

Related tools:

References

References: Carnell et al. 2004. Int J Radiat Oncol Biol Phys. 58(2):500-9. PMID: 14751521. ; Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. ; Maecker et al. 2003. Blood. 102(9):3287-94. PMID: 12869499. ; The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. ; McFadyen et al. 2001. Br J Cancer. 85(2):242-6. PMID: 11461084. ; Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. ; Murray et al. 2001. Annu Rev Pharmacol Toxicol. 41:297-316. PMID: 11264459. ; Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. ; McFadyen et al. 1999. J Histochem Cytochem. 47(11):1457-64. PMID: 10544218. ; Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1.